Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

scPharmaceuticals stock

SCPH
US8106481059
A2H7XD

Price

4.07
Today +/-
-0.07
Today %
-1.95 %
P

scPharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the scPharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the scPharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the scPharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze scPharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

scPharmaceuticals Stock Price History

DatescPharmaceuticals Price
11/1/20244.07 undefined
10/31/20244.15 undefined
10/30/20244.46 undefined
10/29/20244.43 undefined
10/28/20244.37 undefined
10/25/20244.20 undefined
10/24/20244.18 undefined
10/23/20244.37 undefined
10/22/20244.41 undefined
10/21/20244.42 undefined
10/18/20244.53 undefined
10/17/20244.39 undefined
10/16/20244.41 undefined
10/15/20244.26 undefined
10/14/20244.21 undefined
10/11/20244.23 undefined
10/10/20244.08 undefined
10/9/20243.94 undefined
10/8/20243.98 undefined
10/7/20244.07 undefined

scPharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into scPharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by scPharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects scPharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of scPharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into scPharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing scPharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on scPharmaceuticals’s growth potential.

scPharmaceuticals Revenue, EBIT and net profit per share

DatescPharmaceuticals RevenuescPharmaceuticals EBITscPharmaceuticals Net Income
2029e416.48 M undefined0 undefined208.72 M undefined
2028e334.38 M undefined165.82 M undefined162.28 M undefined
2027e291.98 M undefined103.25 M undefined125.02 M undefined
2026e189.66 M undefined34.82 M undefined27.76 M undefined
2025e98.48 M undefined-30.94 M undefined-37.24 M undefined
2024e40.18 M undefined-59.52 M undefined-68.85 M undefined
202313.59 M undefined-55.4 M undefined-54.81 M undefined
20220 undefined-36.16 M undefined-36.84 M undefined
20210 undefined-25.82 M undefined-28.03 M undefined
20200 undefined-29.93 M undefined-32.21 M undefined
20190 undefined-32.91 M undefined-33 M undefined
20180 undefined-29.67 M undefined-29.44 M undefined
20170 undefined-23.44 M undefined-23.82 M undefined
20160 undefined-17.91 M undefined-24.38 M undefined
20150 undefined-10.84 M undefined-10.52 M undefined

scPharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00000000134098189291334416
---------207.69145.0092.8653.9714.7824.55
--------69.23------
000000009000000
-10-17-23-29-32-29-25-36-55-59-30341031650
---------423.08-147.50-30.6117.9935.4049.40-
-10-24-23-29-33-32-28-36-54-68-3727125162208
-140.00-4.1726.0913.79-3.03-12.5028.5750.0025.93-45.59-172.97362.9629.6028.40
17.6117.6118.5318.5618.624.5724.5728.3638.51000000
---------------
Details

Keystats

ⓘ

Revenue and Growth

The scPharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the scPharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201520162017201820192020202120222023
                 
1.639.3118.389.572.6105.175.3118.276.01
000000004.49
000000000
00000001.28.84
0.10.10.922.72.733.93.6
1.739.4119.291.575.3107.878.3123.392.94
0021.71.30.90.50.61.46
000000000
000000000
000000000
000000000
0020020030030030030082
002.21.91.61.20.80.91.54
1.739.4121.493.476.910979.1124.294.48
                 
18.173.10000000
0.66.1173175.2180.8243.8246.2298.9318.56
-18.8-43.2-67-96.5-129.5-161.7-189.7-226.5-281.35
00000000-0
000000000
-0.13610678.751.382.156.572.437.22
0.71.51.60.61.11.70.51.54
1.32.23.13.145.24.55.89.08
0020020000010056
000000000
000.32.802.49.800
23.75.26.75.19.314.87.413.13
009.16.818.916.97.436.838.81
000000000
001.71.51.80.70.47.65.32
0010.88.320.717.67.844.444.13
23.7161525.826.922.651.857.26
1.939.712293.777.110979.1124.294.48
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of scPharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand scPharmaceuticals's financial health and stability.

Assets

scPharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that scPharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of scPharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into scPharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (k)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201520162017201820192020202120222023
-10-24-23-29-33-32-28-36-54
000000000
000000000
01,0000-2,00001,000-2,0000-6,000
082435556
000111225
000000000
-9-15-22-28-30-27-27-34-59
000000000
00000-3332-4519
00000-3332-4520
000000000
0129090-2290
84192046104714
85310201360-27714
---------
000000000
-13779-28-1602-3-24
-9.66-15.47-22.87-28.81-30.44-27.69-27.16-34.6-59.28
000000000

scPharmaceuticals stock margins

The scPharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of scPharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for scPharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the scPharmaceuticals's sales revenue. A higher gross margin percentage indicates that the scPharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the scPharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the scPharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the scPharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the scPharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the scPharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

scPharmaceuticals Margin History

scPharmaceuticals Gross marginscPharmaceuticals Profit marginscPharmaceuticals EBIT marginscPharmaceuticals Profit margin
2029e71.96 %0 %50.11 %
2028e71.96 %49.59 %48.53 %
2027e71.96 %35.36 %42.82 %
2026e71.96 %18.36 %14.64 %
2025e71.96 %-31.42 %-37.82 %
2024e71.96 %-148.12 %-171.34 %
202371.96 %-407.53 %-403.22 %
202271.96 %0 %0 %
202171.96 %0 %0 %
202071.96 %0 %0 %
201971.96 %0 %0 %
201871.96 %0 %0 %
201771.96 %0 %0 %
201671.96 %0 %0 %
201571.96 %0 %0 %

scPharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The scPharmaceuticals earnings per share therefore indicates how much revenue scPharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue scPharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates scPharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of scPharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating scPharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

scPharmaceuticals Revenue, EBIT and net profit per share

DatescPharmaceuticals Sales per SharescPharmaceuticals EBIT per sharescPharmaceuticals Earnings per Share
2029e8.32 undefined0 undefined4.17 undefined
2028e6.68 undefined0 undefined3.24 undefined
2027e5.84 undefined0 undefined2.5 undefined
2026e3.79 undefined0 undefined0.55 undefined
2025e1.97 undefined0 undefined-0.74 undefined
2024e0.8 undefined0 undefined-1.38 undefined
20230.35 undefined-1.44 undefined-1.42 undefined
20220 undefined-1.28 undefined-1.3 undefined
20210 undefined-1.05 undefined-1.14 undefined
20200 undefined-1.22 undefined-1.31 undefined
20190 undefined-1.77 undefined-1.77 undefined
20180 undefined-1.6 undefined-1.59 undefined
20170 undefined-1.26 undefined-1.29 undefined
20160 undefined-1.02 undefined-1.38 undefined
20150 undefined-0.62 undefined-0.6 undefined

scPharmaceuticals business model

scPharmaceuticals Inc is a US pharmaceutical company based in Lexington, Massachusetts. The company was founded in 2013 and currently employs over 100 staff members. It specializes in the development and marketing of innovative drugs for chronic diseases. The company's business model focuses on the development of drugs in the areas of cardiovascular, renal function, and infectious diseases. The goal is to provide better treatment options for patients suffering from chronic diseases than current therapies. The company relies on innovative technologies to improve the effectiveness and tolerability of the developed medications. One of scPharmaceuticals' core areas is cardiovascular therapy. The company is working on the development of a drug called Furoscix™ for the treatment of patients with acute heart failure. Furoscix™ is a convenient, portable infusion system that allows patients to receive the medication at home or in an outpatient facility instead of staying in a hospital. Currently, Furoscix™ is in Phase 3 clinical trials, and results are still pending. Another core area for scPharmaceuticals is kidney therapy. The company is developing a drug called SC-001 for the treatment of patients with chronic kidney insufficiency. SC-001 is a novel medication based on innovative technology that allows the body to break down the drug more slowly, leading to a longer duration of action. Together with other products, such as a midazolam nasal spray for sedation during endoscopies or a fentanyl nasal spray for pain management after surgeries, scPharmaceuticals is working to revolutionize drug therapy and improve patients' quality of life. The company's history is marked by various stages of development. In 2014, scPharmaceuticals received funding of $16.8 million from various investors, including venture capital firms and strategic partners from the pharmaceutical and biotech industry. In 2018, the company went public on the Nasdaq stock exchange and sold shares worth approximately $90 million. These financings enabled the clinical development and future marketing of Furoscix™ and other medications. scPharmaceuticals aims to develop innovative solutions for patients with chronic diseases and provide better treatment options. The company works closely with physicians, hospitals, and patient groups to understand and cater to the needs of its user groups. With advanced technology and the latest medical knowledge, scPharmaceuticals is working to develop the medications of the future. scPharmaceuticals is one of the most popular companies on Eulerpool.com.

scPharmaceuticals SWOT Analysis

Strengths

  • Strong portfolio of innovative pharmaceutical products
  • Advanced research and development capabilities
  • State-of-the-art manufacturing facilities
  • Strong financial position
  • Significant market share in key therapeutic areas

Weaknesses

  • High dependence on a limited number of products
  • Relatively small size compared to industry giants
  • Limited geographical presence
  • Vulnerable to regulatory changes and government policies

Opportunities

  • Increasing demand for innovative pharmaceutical solutions
  • Expansion into untapped markets and regions
  • Growing aging population and prevalence of chronic diseases
  • Strategic partnerships and collaborations
  • Technological advancements in drug delivery systems

Threats

  • Intense competition in the pharmaceutical industry
  • Inherent risks and complexities associated with clinical trials
  • Stringent regulatory requirements for product approvals
  • Potential loss of key patents and intellectual property rights
  • Economic instability and pricing pressures

scPharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

scPharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

scPharmaceuticals shares outstanding

The number of shares was scPharmaceuticals in 2023 — This indicates how many shares 38.514 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue scPharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates scPharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of scPharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating scPharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for scPharmaceuticals.

scPharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.42 -0.44  (-4.19 %)2024 Q2
3/31/2024-0.45 -0.36  (19.23 %)2024 Q1
12/31/2023-0.43 -0.35  (18.07 %)2023 Q4
9/30/2023-0.37 -0.41  (-10.19 %)2023 Q3
6/30/2023-0.38 -0.36  (5.21 %)2023 Q2
3/31/2023-0.37 -0.3  (19.42 %)2023 Q1
12/31/2022-0.39 -0.3  (23.99 %)2022 Q4
9/30/2022-0.39 -0.37  (5.18 %)2022 Q3
6/30/2022-0.31 -0.35  (-13.12 %)2022 Q2
3/31/2022-0.32 -0.28  (11.45 %)2022 Q1
1
2
3

Eulerpool ESG Scorecard© for the scPharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

46/ 100

🌱 Environment

52

👫 Social

27

🏛️ Governance

58

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

scPharmaceuticals shareholders

%
Name
Stocks
Change
Date
12.11179 % OrbiMed Advisors, LLC6,059,528500,0008/13/2024
7.04577 % Rubric Capital Management LP3,525,00006/30/2024
5.20985 % AIGH Capital Management, LLC.2,606,49058,5216/30/2024
4.40764 % Luther King Capital Management Corp.2,205,140394,3016/30/2024
4.33276 % Sun Pharmaceutical Industries Ltd2,167,67904/16/2024
3.64828 % Lytton (Laurence W)1,825,2341,825,2344/17/2024
3.23618 % BlackRock Institutional Trust Company, N.A.1,619,061-42,5596/30/2024
2.77073 % The Vanguard Group, Inc.1,386,19616,3606/30/2024
2.39985 % 5AM Ventures1,200,64706/30/2024
2.06690 % Thrivent Asset Management, LLC1,034,072-32,6326/30/2024
1
2
3
4
5
...
10

scPharmaceuticals Executives and Management Board

Mr. John Tucker(60)
scPharmaceuticals President, Chief Executive Officer, Director (since 2017)
Compensation 1.6 M
Ms. Rachael Nokes(48)
scPharmaceuticals Chief Financial Officer
Compensation 1.05 M
Mr. Jack Khattar(61)
scPharmaceuticals Independent Chairman of the Board
Compensation 132,657
Mr. Frederick Hudson(77)
scPharmaceuticals Independent Director
Compensation 107,657
Ms. Minnie Baylor-Henry(75)
scPharmaceuticals Independent Director
Compensation 97,657
1
2
3

scPharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
West Pharmaceutical Stock
West Pharmaceutical
SupplierCustomer0,210,580,680,200,25-0,62
1

Most common questions regarding scPharmaceuticals

What values and corporate philosophy does scPharmaceuticals represent?

scPharmaceuticals Inc is a progressive healthcare company focused on revolutionizing the way acute care and chronic care are delivered. The company believes in promoting patient-centric solutions that simplify and improve treatment for patients with cardiovascular and infectious diseases. scPharmaceuticals Inc takes pride in its commitment to delivering innovative and practical solutions that enhance patient outcomes. With a strong emphasis on research and development, the company is dedicated to advancing medical science and improving patient care. scPharmaceuticals Inc's corporate philosophy is rooted in accountability, integrity, and patient advocacy, ensuring a strong foundation for its continued growth and success.

In which countries and regions is scPharmaceuticals primarily present?

scPharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company scPharmaceuticals achieved?

scPharmaceuticals Inc has achieved several significant milestones in its history. The company successfully developed and gained regulatory approval for its innovative subcutaneous formulation of furosemide, which enables the delivery of diuretic treatment to heart failure patients outside of the hospital setting. Additionally, scPharmaceuticals Inc initiated and completed a successful Phase III clinical trial for its lead product in acute and chronic heart failure patients. The company also secured multiple patents and expanded its product pipeline for the treatment of various conditions. These achievements demonstrate scPharmaceuticals Inc's commitment to developing novel therapies and improving patient care in the pharmaceutical industry.

What is the history and background of the company scPharmaceuticals?

scPharmaceuticals Inc is a pharmaceutical company that specializes in developing and commercializing transformative pharmaceutical products. Founded in [year], scPharmaceuticals aims to revolutionize the treatment of acute and chronic conditions through its innovative products. The company has a strong focus on delivering medications through the subcutaneous route, enhancing convenience and patient experience. With its cutting-edge technology and dedicated team, scPharmaceuticals has gained recognition and made significant advancements in the healthcare industry. As a leading player in the pharmaceutical sector, scPharmaceuticals Inc continues to strive towards improving patient outcomes and addressing unmet medical needs.

Who are the main competitors of scPharmaceuticals in the market?

Some of the main competitors of scPharmaceuticals Inc in the market include Akebia Therapeutics, Correvio Pharma Corp, and NephroGenex.

In which industries is scPharmaceuticals primarily active?

scPharmaceuticals Inc is primarily active in the biopharmaceutical industry.

What is the business model of scPharmaceuticals?

The business model of scPharmaceuticals Inc focuses on developing and commercializing innovative pharmaceutical products. The company aims to provide convenient and reliable alternative therapies for patients in need. By utilizing its proprietary technology, scPharmaceuticals Inc creates and delivers ready-to-use, subcutaneous medications. These products are designed to be self-administered by patients in various healthcare settings, including hospitals and homes. scPharmaceuticals Inc’s business model aims to improve patient experience and outcomes by providing effective and convenient treatment options.

What is the P/E ratio of scPharmaceuticals 2024?

The scPharmaceuticals P/E ratio is -2.28.

What is the P/S ratio of scPharmaceuticals 2024?

The scPharmaceuticals P/S ratio is 3.9.

What is the Quality Investing of scPharmaceuticals?

The Quality Investing for scPharmaceuticals is 3/10.

What is the revenue of scPharmaceuticals 2024?

The expected scPharmaceuticals revenue is 40.18 M USD.

How high is the profit of scPharmaceuticals 2024?

The expected scPharmaceuticals profit is -68.85 M USD.

What is the business model of scPharmaceuticals

ScPharmaceuticals Inc is an American company that develops and markets drugs that can be used directly at the site of the patient's illness. This means that the drugs are not taken intravenously or orally as usual, but can be injected directly under the skin as a subcutaneous therapy (SC). The company has several divisions: The first includes drugs for the treatment of heart failure that can be injected directly at the site of the illness. The main product of this division is the Furoscix injection system, which is used to treat fluid accumulation in patients with acute heart failure. The system allows hospitals and other medical facilities to perform this important treatment on an outpatient basis. The second division of the company includes drugs for the treatment of highly acute migraines. These drugs are also injected directly at the site of the illness to achieve rapid effects when other medications do not work. Another product of the company is the infusion system, which is used for the treatment of patients in the hospital. This system allows for faster administration of medications and improves the treatment of critically ill patients. ScPharmaceuticals has also developed an innovative system that simplifies the administration of antibiotics in patients with cystic fibrosis. The typical antibiotics for the treatment of this condition are time-consuming and complex to use. ScPharmaceuticals has developed a system that makes them easier and faster, which is a great advantage for patients. The business model of ScPharmaceuticals focuses on the development and sale of medications that take place directly at the site of the illness, as well as the sale of accessories and related devices. By focusing on this niche, the company can develop innovative products and respond faster to the needs of patients. ScPharmaceuticals has an experienced management team and has close relationships with providers of medical devices and accessories. Through close collaboration with these partners, the company can quickly respond to new market developments. In summary, the business model of ScPharmaceuticals is based on the development of innovative drugs for the treatment of diseases at the site of the illness. The company specializes in a niche and focuses on collaborating with partners in the medical technology industry to be able to quickly respond to the needs of patients.

What is the scPharmaceuticals dividend?

scPharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does scPharmaceuticals pay dividends?

The dividend cannot currently be calculated for scPharmaceuticals or the company does not pay out a dividend.

What is the scPharmaceuticals ISIN?

The ISIN of scPharmaceuticals is US8106481059.

What is the scPharmaceuticals WKN?

The WKN of scPharmaceuticals is A2H7XD.

What is the scPharmaceuticals ticker?

The ticker of scPharmaceuticals is SCPH.

How much dividend does scPharmaceuticals pay?

Over the past 12 months, scPharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, scPharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of scPharmaceuticals?

The current dividend yield of scPharmaceuticals is .

When does scPharmaceuticals pay dividends?

scPharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of scPharmaceuticals?

scPharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of scPharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is scPharmaceuticals located?

scPharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von scPharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of scPharmaceuticals from 11/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/3/2024.

When did scPharmaceuticals pay the last dividend?

The last dividend was paid out on 11/3/2024.

What was the dividend of scPharmaceuticals in the year 2023?

In the year 2023, scPharmaceuticals distributed 0 USD as dividends.

In which currency does scPharmaceuticals pay out the dividend?

The dividends of scPharmaceuticals are distributed in USD.

All fundamentals about scPharmaceuticals

Our stock analysis for scPharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of scPharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.